Related Practices
Axinn is the go-to firm for IP matters of strategic importance. The firm has numerous seasoned IP trial lawyers, typically has several dozen patent cases pending at a time, tries multiple patent cases annually and has served as lead counsel in some of the most significant recent patent trials, including the defense of a multi-billion dollar jury trial. On many occasions, the firm has been asked to take over pending cases and serve as lead trial counsel.
Axinn attorneys also offer exceptional depth of technical training and patent counseling experience. Axinn seeks to partner with its clients in the ongoing management of their IP portfolios, product launches and defensive issues. To help its clients execute their business plans, the firm marshals all of its skills and experience in law, science, business and (when necessary) litigation.
Axinn offers skills and experience in numerous industries and technologies, including all areas of life sciences, chemicals, mechanical, electronics and software. In addition, the firm has an extensive FDA litigation and counseling practice.
Axinn is also well-positioned to handle issues and cases at the intersection of antitrust and intellectual property. The firm regularly litigates antitrust counterclaims in IP cases, and counsels clients on issues such as patent pooling, the legality of settlement and license agreements and patent misuse.
News
- Axinn Recognized in Eleven Categories of "Best Law Firms" Report
- Nine Axinn Attorneys Named to the US District Court for the District of Connecticut 2023 Pro Bono Honor Roll
- Axinn Partners Named Life Sciences Stars by LMG Life Sciences
- Axinn Partner Jeannine Sano Ranked by IAM Strategy 300: The World’s Leading IP Strategists 2023
- Axinn Team Receives Am Law "Litigator of the Week" Shout Out for Representation of Hobby Lobby
- Six Axinn Attorneys Named to Empire State Counsel Program
- Commission Affirms Axinn’s ITC Victory for Hobby Lobby
- Axinn Partners Named to 2024 Lawdragon 500 Leading Litigators in America
- Jeannine Sano Named to The Recorder’s List of 30 Women Leaders in Tech Law
- Axinn Ranks Among Nation’s Top Firms in 2023 ANDA Intelligence Report
- Axinn Attorneys Named to Best Lawyers 2024
- Axinn Secures Asylum on Behalf of Pro Bono Client
- Axinn to Participate in Diversity Lab’s Mansfield Rule Certification Process for Midsize Law Firms
- Axinn Partner Brian Johnson Named to Bloomberg Law's Top 40 Under 40
- Four Axinn Attorneys Named to Capital Pro Bono Honor Roll
- Axinn Shortlisted for Three 2023 LMG Life Sciences Americas Awards
- Axinn Secures Asylum for Pro Bono Client
- Axinn Named to Vault “Top 150 Under 150” for 2024
- Jason Murata Named a Profiles in Diversity Journal Asian Leadership Award Winner
- Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
- Chambers USA 2023 Recognizes Axinn Lawyers and Practice Groups
- Managing IP STARS Selected Axinn IP Partner Jeannine Yoo Sano as a 2023 Patent Star in CA
- Axinn Welcomes Experienced Patent Litigator Brian Johnson to Washington, DC Office
- Axinn Scores Multiple IPR Victories on Behalf of Applied Materials
- Axinn Promotes Craig Minerva to Partner, Rebecca Clegg and Kail Jethmalani to Counsel
- Axinn Recognized in Eleven Categories of "Best Law Firms" Report
- Axinn Partners Named Life Sciences Stars by LMG Life Sciences
- Axinn Ranks Among Nation’s Top Firms in 2022 ANDA Intelligence Report
- Axinn Partners Named to Lawdragon 500 Leading Litigators in America
- Axinn Attorneys Named to Best Lawyers 2023
- Who's Who Legal Recognizes Ten Axinn Attorneys
- Litigator of the Week Honors for Patent Trial Success
- Axinn Achieves Trial Success for Norwich Pharmaceuticals as it Seeks to Market a Generic of Xifaxan®
- Commission Affirms Axinn’s ITC Victory for Thales
- Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
- Chambers USA 2022 Recognizes Axinn Lawyers and Practice Groups
- Managing IP STARS Selected Axinn IP Partner Jeannine Yoo Sano as a 2022 Patent Star in CA and Recommended Axinn in CT for IP
- Axinn Associate Rebecca Clegg Named a Connecticut Law Tribune "New Leader in the Law"
- Axinn Promotes Matthew Murphy to Partner, James Hunsberger, Melanie Kiser, and Michael O'Mara to Counsel
- Axinn Recognized in Ten Categories of "Best Law Firms" Report
- Axinn Ranks Among Nation’s Top Firms in 2021 ANDA Intelligence Report
- Axinn Partners Ranked as Litigation Stars in the 2022 Edition of Benchmark Litigation
- Axinn Partners Named Life Sciences Stars by LMG Life Sciences
- Axinn Attorneys Named to Best Lawyers 2022
- Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
- Chambers USA 2021 Recognizes Axinn Lawyers and Practice Groups
- Axinn Moves Washington, D.C. Office to New LEED Gold Status and WELL Certified Space
- Six Axinn Attorneys Named to Capital Pro Bono Honor Roll
- Axinn Partner Stacie Ropka Named to The Center for Biosimilars’ Board of Advisors
- Axinn Recognized in Ten Categories of "Best Law Firms" Report
- The District of Columbia Courts Recognize Four Axinn Attorneys in its 2019 Capital Pro Bono Honor Roll
- Matthew Becker Named an Intellectual Property Trailblazer by The National Law Journal
- Three Axinn partners named "Life Sciences Stars" in LMG Life Sciences 2020
- The 2021 Edition of Benchmark Litigation has selected Axinn as a “Recommended Firm” and named four Axinn partners as IP “Litigation Stars” in CT and DC
- Axinn Attorneys Named to Best Lawyers 2021
- Managing IP STARS Selected Axinn IP Partner Jeannine Yoo Sano as a 2020 Patent Star in CA and Recommended Axinn in CT for IP
- Axinn and IP Partners Ranked by IAM Patent 1000: The World’s Leading Patent Professionals
- Jeannine Yoo Sano Named a Profiles in Diversity Journal Woman Worth Watching
- Chambers USA 2020 Recognizes Axinn Lawyers and Practice Groups
- Chad Landmon Named to NLJ’s List of Health Care/Life Sciences Trailblazers
- Axinn Continues West Coast Expansion with Addition of Three Senior Intellectual Property Litigators
- Federal Circuit Affirms Axinn’s Trial Victory for Alvogen
- Axinn Recognized in Nine Categories of "Best Law Firms" Report
- Chad Landmon named a "Life Sciences Star" in LMG Life Sciences 2019
- The 2020 Edition of Benchmark Litigation has selected Axinn as a “Recommended Firm” and named four Axinn partners as IP “Litigation Stars” in CT and DC
- Axinn Partners Named to Best Lawyers 2020
- Axinn Received Outstanding Achievement Award for Pro Bono Work
- Chambers USA 2019 Recognizes Axinn Lawyers and Practice Groups
- Axinn’s Client Awarded Attorneys’ Fees in “Exceptional” PIV Case
- Axinn Obtains Favorable Settlement for Pro Bono Client
- Connecticut Law Tribune Named Axinn Intellectual Property Litigation Department of the Year
- Axinn Named a "Legal Lion" for Federal Circuit Patent Win
- Axinn Promotes Bradley Justus and Matt Murphy to Counsel
- Axinn Recognized in Nine Categories of "Best Law Firms" Report
- Axinn Launches California Office, Bringing Elite Antitrust and IP Practices to West Coast
- Axinn Successfully Secures Asylum for Pro Bono Client
- Axinn Named "Intellectual Property Firm to Watch" at the LMG Life Sciences Awards 2018
- Axinn Leads Alvogen to Victory in Hatch-Waxman Case for Generic Zohydro®
- Eight Axinn Partners Named to Best Lawyers 2019
- Axinn Sponsors Travelers Championship 2018
- Axinn Successfully Defeats a Motion to Dismiss on Behalf of Pro Bono Client
- Chambers USA Recognizes Axinn Practice Groups
- Chambers USA Recognizes Seven Axinn Partners
- Axinn Sponsors Genomics Lab at Connecticut Science Center
- Stacie Ropka Named Among Hartford Business Journal's Remarkable Women in Business
- The Connecticut Law Tribune Honors Two Axinn Attorneys
- New York State Bar Recognizes Eleven Axinn Attorneys
- Axinn Promotes Jeny Maier and Jason Murata
- Axinn Recognized in Eight Categories of "Best Law Firms" Report
- Seven Axinn Partners Named to the 2018 List of Best Lawyers in America
- Federal Circuit Rules for Axinn Client in Abilify Patent Appeal
- Axinn Sponsors Travelers Championship
- Chambers USA Recognizes Axinn Practice Groups
- Six Axinn Partners Recognized by Chambers USA
- Dr. Stacie Ropka Identified as a Woman Worth Watching in STEM® Award Winner
- Axinn Promotes Stacie Ropka and Jeny Maier
- Axinn Successfully Argues for Claim Construction in Mayne v. Merck
- Axinn Successfully Obtains Dismissal of Certain Patent Claims asserted against Zydus Pharmaceuticals in Boehringer Ingelheim Pharmaceuticals, Inc. v. HEC Pharma Co., Ltd.
- Axinn Earns Six Tier 1 Categories in "Best Law Firms"
- Axinn Named IP Litigation Department of the Year
- Six Axinn Partners Named to the 2017 List of Best Lawyers in America
- Axinn Defeats TRO, Enabling Immediate Launch of Generic Versions of AstraZeneca’s Blockbuster Crestor
- Axinn Named to The National Law Journal’s 2016 Midsize Hot List
- Axinn Obtains Stipulated Summary Judgment of Non-Infringement for Zydus
- Axinn Expands IP and Regulatory Practice with Partner Aziz Burgy
- Axinn Recognized in Six Categories of "Best Law Firms" Report
- Axinn Successfully Obtains Dismissal for Zydus Pharmaceuticals
- Axinn Partners Named to the 2016 List of Best Lawyers in America
- Axinn Obtains Denial of a TRO Motion for Client Zydus
- Axinn Partners Ranked by Chambers in Global Guide
- Axinn Named Litigation Department of the Year
- Axinn Promotes Rachel Adcox and John Tanski to Partner; Thomas Hedemann to Counsel
- Axinn Successful In Protecting FDA Approval for Client Endo Pharmaceuticals Inc.
- Axinn Earns Six Tier 1 Categories in "Best Law Firms"
- Matt Becker, Jim Veltrop, John Briggs, Steve Axinn and Fran Morrison Named to the List of 2015 Best Lawyers in America
- Jason Murata Selected as New Leader in the Law
- Axinn Granted Summary Judgment in Delaware Federal Court
- Axinn Named to The National Law Journal's Midsize Hot List
- Axinn Honored With Litigation Department of the Year
- Federal Circuit Rules for Axinn Client in Tamiflu Patent Appeal
- Chad Landmon Named to Law360's Intellectual Property "Rising Star" List
- Entire Market Value Rule Vs. 'Convoyed Sales' Rule
- Longtime FTC Veteran Richard Dagen Joins Axinn
- Axinn Promotes Daniel Bitton and Stacie Ropka
- Axinn Wins $16 Million Damages Award for Medical Device Client at Jury Trial in Delaware
- Chad Landmon Receives University of Connecticut Distinguished Alumni Award
- Chad Landmon Named to Law360's Life Sciences "Rising Star" List
- Axinn Obtains Favorable Decision in FDA Suit
- Axinn Partner Chad Landmon Honored as a "New Leader in the Law"
- Axinn Obtains Summary Judgment Victory Against FDA
- Axinn Assisted Actavis in Resolving Ten-Year-Old Dispute with Pfizer
- Axinn Successful in Protecting Client Alvogen's Entry to Drug Market
- Axinn Partners Named Connecticut "Rising Stars" 2011/2012
- Axinn Partner Chad Landmon Honored as Hartford Business Journal “40 Under 40” Winner
- Axinn Partner Pens Article on Biosimilar Approval Standards Under BPCI
- On March 17, 2011, Chad Landmon Discussed Bioequivalence at ACI's FDA Boot Camp
- On February 3, 2011, Chad Landmon Presented on the FDA Hearings on the BPCI Act at the AIPLA Mid-Winter Institute
- Matthew Becker Speaks With PharmaWire on the Potential Patent Life of BTC and Johnson & Johnson’s Abiraterone Drug For Prostate Cancer
- Chad Landmon Presented on Bioequivalence in Boston
- Axinn Partner Chad Landmon Speaks with Pharmawire about Johnson & Johnson Facing Further Regulatory Scrutiny
- Axinn's Partner Chad A. Landmon Quoted by The Pink Sheet Discussing the Lovenox Lawsuit
- Landmon Quoted by Pharmawire on the Possibility of a Cephalon Settlement
- Landmon Provides Insights on Generics Challenge of AstraZeneca's Crestor Patents to Pharmawire
- Landmon Discusses Teva's Launch of Generic Cozaar/Hyzaar With Market Exclusivity with The Pink Sheet
- Chad Landmon Discusses a Recent U.S. Court of Appeals Ruling with The Pink Sheet
- Axinn Wins Summary Judgment on Behalf of Mutual Pharmaceutical Company
- Axinn Partner Chad Landmon Discusses "pay-for-delay" Legislation in White House Health Care Plan
- Axinn's Chad Landmon Discusses the Likelihood of the FTC Increasing Efforts to Obtain Passage of "Pay-For-Delay" Legislation with Drug Industry Daily
- Chad Landmon Discusses At-Risk Launches with The Pink Sheet Daily
- Chad Landmon Discusses Report on Generic Drug Availability with Generic Line
- Chad Landmon Discusses Astellas Court Loss with Generic Line
- Chad Landmon Discusses Cubist's Lawsuit Against Teva with Pharmawire
- Axinn's Chad Landmon Speaks with Drug Industry Daily About the Drug Price Competition Act of 2009
- Chad Landmon Participates in Question and Answer Session with The National Law Journal on Follow-On Biologics
- Chad Landmon Discusses Court Decision Enjoining Teva from Launching Generic Osteoporosis Drug with Generic Line
- Chad Landmon Discusses Novartis’ Exjade® with Pharmawire
- Chad Landmon Discusses Court Rulings and Patent Law Reform with Thomson-Reuters
- Chad Landmon Discusses Teva's At-Risk Launch of Generic Pulmicort with The Pink Sheet
- Chad Landmon Discusses FDA's Letter Ruling Practice with The Pink Sheet
- CBI's Pharmaceutical Congress on Paragraph IV Disputes -- Chad Landmon Discusses Litigation Strategies, Generic Exclusivity Forfeiture and Recent Developments in Paragraph IV Disputes
- Chad Landmon Discusses Recent Declaratory Judgment Ruling with The Pink Sheet
- Pfizer Buys More Time for Lipitor
- Matt Becker participates in GC New England Roundtable on Patent Litigation
- Law Article May Spark Patent Litigation Strategy
- The Best and Worst Patents for Generics to Fight
- Chad Landmon Discussess generic exclusivity forfeiture provisions with IP Law360
- Michael Keeley and Chad Landmon discuss FDA's recent 180-day exclusivity decisions with FDAnews
- FDAnews Audioconference -- Navigating the FDA's New 180-Day Generic Marketing Exclusivity Rulings
- Firm Gears Up For High Stakes Drug Lit
- Jim Veltrop Featured in IP360
- Cantor Colburn's Michael Cantor plugs Jim Veltrop in IP Law 360
- IP Litigation: Fran Morrison Comments on Qualcomm Legal Issues in Wall Street Journal and The Recorder
- Axinn Represents INEOS in U.S. Litigation
- Axinn Serving as Patent Counsel for ADHD and Pain Relief Medications
- Axinn Continues to Expand Its Intellectual Property Group
- Axinn Represents URL/Mutual Companies in Launch of Guaifenesin Products
- Axinn Defends Fila in Marshall, Texas Patent Action
- Axinn Expands Its Intellectual Property Group
- Axinn Represents Sport Brands International/FILA in Connection with Launch of Various Products
- Axinn Represents R.R. Donnelly in Patent and Antitrust Litigation
- Axinn Represents Purepac Pharmaceutical Company in Metformin Launch
- Axinn Represents Stanley Works in Patent Litigation
- Stanley Defends Its Colors, Trade Turfs
- Axinn Defends Ryobi Technologies, Inc.
- View More ›
Publications
- What’s at Stake in Bystolic 'Side Deals' Litigation
- 3 Areas Look Ripe for New SEP Licensing, Litigation
- Axinn IP Update: Federal Circuit Applies Lead Compound Analysis and Confirms Obviousness of Deuterated Derivatives of Ruxolitinib
- How to Avoid the Section 101 Pitfall in Blockchain Patenting
- Axinn IP Update: Federal Circuit Clarifies Permissible Scope of Petitioner Reply
- Axinn IP Update: District of Delaware Magistrate Judge Recommends Dismissal of Claims of Induced Infringement in Skinny Label Case
- 'Intended Purpose' of a Flower: Gauging Patent Invalidity Based on the Public Use of Plants and Genetic Information
- Supreme Court Confirms Full Scope Enablement Standard in Amgen v. Sanofi
- Would Congress' Proposed ITC Reforms Thwart NPEs?
- Effects of GSK v Teva Ripple after SCOTUS Denies Cert
- FDA's Digital Health Technologies Framework Addresses Important Challenges
- Axinn IP Update: Supreme Court Denies Cert. in Skinny Label Case, but the Impacts from GSK v. Teva Continue
- USPTO’s ANPRM Sets the Stage for Latest Revamp of the Discretionary Denial Process
- Axinn IP Update: The Supreme Court Hears Arguments About the Enablement Standard in Amgen v. Sanofi
- Resistance or Defiance? The FDA and the 11th Circuit Spar Over Statute on Orphan Drug Statutory Exclusivity
- Federal Circuit Reverses Course on ‘Appropriate Deference’ in Indefiniteness Determinations
- The Regulatory Labyrinth of Stem Cell Treatments
- Axinn IP Update: Federal Circuit Confirms That Prosecution Disclaimer Is Not Binding on the Patent Office in an Ongoing PTAB Proceeding But Will Bind Future Proceedings
- Pharmaceutical Supply Chain – Patent Considerations
- When a Claimed Trade Secret Isn't in Fact a Secret
- The Uncertain Future of Patent Indefiniteness Under Federal Circuit's Deference Standard
- China’s New Privacy and Data Security Statutes Further Complicate U.S. Litigations
- Axinn IP Update: Federal Circuit Denies Petition for Rehearing En Banc in GSK v. Teva
- Axinn IP Update: Federal Circuit Confirms That AAPA Cannot Be the Basis for IPRs, But Leaves the “Basis” Determination Question Open
- The Center for Biosimilars Interview Series: Legal Perspectives in Biosimilars
- Axinn IP Update: Proposed Legislation Aims at "Restoring the America Invents Act"
- Happy 10th Birthday
- SCOTUS Decides Arthrex: Much Ado About Inter Partes Reviews
- The Center for Biosimilars Interview: Axinn IP Chair Provides Analysis of Biden Biosimilars Initiative
- New U.S. Legislation Creates Momentum for Biosimilars
- Will Skinny Labelling Survive?
- IP and Collaboration
- Interview on the FDA’s Emergency Use Authorization Process for COVID-19 Vaccines
- Axinn IP Update: Where is the Federal Circuit Heading in the Skinny Labeling Case?
- Axinn IP Update: Federal Circuit Says Functional Patent Claims Must Clear "High Hurdles"
- Axinn IP Update: Federal Circuit Agrees to Reconsider Controversial “Skinny Label” Decision
- Member Spotlight: Francis H. Morrison
- How President-Elect Biden’s Cabinet Nominations May Impact Pharmacy This Year
- Frandly Fire
- When Japanese Witnesses Testify in U.S. Courts: Answers to Nine Common Concerns
- Our Journey to Voting by Mail-In Ballot in North Carolina in 2020
- How Justice Barrett’s Confirmation Might Impact Patent Eligibility
- Top 10 IPR Pitfalls at the Institution Stage
- What the Potential Elimination of the Biologics Price Competition and Innovation Act Means for Pharmacy
- Axinn FDA Update: Insights on the MODERN Labeling Act
- Seeking "Mens Sana in Corpore Sano" in a Pandemic
- Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge
- The 2020 Axinn Survey of U.S. Litigation Involving Japanese Companies
- Axinn FDA Update: A Difficult Analysis Is Not Necessarily a Deferential Analysis
- Tuning in to Covered Business Method Review's Series Finale
- Inclusion Matters, Now More Than Ever: Practical Suggestions for Making a Difference
- Axinn IP Update: District Court Retains Subject Matter Jurisdiction But Grants Dismissal After Paragraph III Conversion
- IPR: The End of the Road for Fifth Amendment Challenges?
- Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins
- A Close Look at European Union's AI Regulation Proposal
- The 2019 Axinn Survey of U.S. Litigation Involving Japanese Companies
- Balancing Settlements, Motions After Fed. Circ. Serta IP Ruling
- Axinn IP Update: Six Patents Directed to Humanized Monoclonal Antibodies Fall at PTAB
- Axinn IP Update: Settlement Practice in Light of Pending Motions
- Pharmaceutical Experience Matters in Defending Pharmaceutical Securities Cases
- Axinn IP Update: SCOTUS Passes on Refining Subject Matter Eligibility Doctrine
- Axinn IP Update: No “Single-Entity” Requirement for Section 271(g) Liability
- Axinn IP Update: Federal Circuit Addresses BPCIA Safe Harbor, Damages
- Fed Circ. Ruling May Affect Eligibility of Life Sciences Patents
- Axinn IP Update: Section 287(c) Immunity Has Its Limits
- Curing the Drug Label as Prior Art Malady at the PTAB
- New Calif. Pay-For-Delay Law May Hurt Those It Aims to Help
- Protecting Intellectual Property in the Era of Intelligent Machines
- Axinn IP Update: No Collateral Estoppel after PTAB Ruling on IPR
- Failure to Launch: The Patent Thicket Delay of US Biosimilars
- Axinn IP Update: PTAB Abused its Discretion in Denying Patentee Leave to Correct Chain of Priority
- Fed. Circ. Muddies Waters on Method-Of-Treatment Patents
- Fixing the Follow-On Insulin Regulatory Approval "Dead Zone"
- Axinn IP Update: Federal Circuit Says Method of Treatment Claims Are Not Per Se Eligible Under Section 101
- Axinn Insights on U.S. Litigation for Japanese Companies: The Duty to Preserve Documents and Implement Litigation Holds in U.S. Civil Litigation
- Biologic Labels and Induced Patent Infringement: A Perspective on Evolving U.S. Law
- Justices May Be Ready to Narrowly Overturn 'Auer'
- Axinn IP Update: Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals, Inc.
- Axinn IP Update: U.S. Supreme Court Holds That Copyright Office Must Grant Copyright Registration Before Infringement Suit Can Be Filed
- Method-of-Treatment Patent Eligibility: Step 1 and Done?
- A Hard Choice for Abbreviated Biologics License Applicants
- Axinn IP Update: Federal Circuit Affirms No Public Use Via Implied Confidentiality
- Axinn IP Update: U.S. Supreme Court Ruling Leaves On-Sale Bar Unchanged
- Patent Dance Developments: A Tale of 2 Antibodies
- Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Second Edition
- The CRISPR Tug of War
- Integrating Trade Secrets into a Comprehensive IP Strategy
- 2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
- Joint Infringement Post-Akamai Part Two: Decisions Since Akamai and Practice Insights
- Joint Infringement Post-Akamai Part One: Exploring the New Joint Infringement Standard
- How Much Detail Should You Provide in a Patent Infringement Complaint?
- Recent Developments in Japanese and U.S. Trade Secret Laws
- Data Analytics to Identify Hot Spots in Obviousness Challenges
- FDA Regulation of HCT/Ps – Impact of New Guidances on Manufacturers and Users
- Now Comes The Hard Part: Sandoz Must Sell Its Biosimilar
- A Call for Antibody Quality Control
- 5 Lessons We Can Learn from FDA’s First Biosimilar Review
- Protecting Business Trade Secrets When Working Abroad
- Should The Entire Market Value Rule Apply To Lost Profits?
- Law360's Q&A With Axinn's Matthew Becker
- 2012 Court Decisions Impact the Life Science Industry
- Use of License Agreements to Determine Reasonable Royalties
- Brand's Off-Label Promotion: Valuable Tool for Generics
- Innovative Procedures v. Premarketing Approval
- Machine-Or-Transformation Test After Myriad: Implications To The Prosecution Of Process Claims
- Heightened Standard For The Entire Market Value Rule?
- Human Tissue and Stem Cell Therapies: Revolutionary New Therapies that Face Increasing FDA Scrutiny
- Federal Circuit Draws the Line on DJ Jurisdiction
- FDA's Exclusivity Forfeiture Saga Continues
- Raising the Bar of Patentability
- Here Comes The Tidal Wave of Generic DJ Actions
- FDA Removes Teeth From Exclusivity Forfeiture
- What is Patentable?
- Supreme Court Backhands Key Federal Circuit Test
- FTC Rules That Deception Regarding Patents During Standard Setting Process Violates Antitrust Laws
- Fourth Circuit Rejects Another Authorized Generics Challenge
- On Demand: Focusing The Patent Scope
- FDA's "Holding On The Merits" Test
- Recent Court Rulings Indicate That Patent Rights May Trump the Antitrust Laws
- Supreme Court Abandons Presumption of Market Power in Patent-Tying Cases
- The "Narrowed Claim Conundrum" Resulting from Reissue and Reexamination Proceedings
- The Impact of a Brand Generic Launch on the Recovery of Patent Damages
- "Schering" Overruled: Risk of Settling Patent Suits Reduced?
- Invention is the Mother of Litigation
- Trade Secret Misappropriation A Federal Crime
- View More ›
Chair
Other Contacts
Speaking Engagements & Seminars
- Magna Legal Services Battle of the Experts 2023
- Stakeholders 23rd Annual CYOC Career Development Conference
- Centerforce Diverse Rainmaker Summit: Excellence in Business Development 2023
- IAM Connect Patent Policy and Litigation Conference 2023
- NAPABA Convention 2023
- IBA Annual Conference 2023
- ACI 3rd Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
- Connecticut Tech Council 18th Annual Women of Innovation Awards
- EDTX Bench Bar Conference 2023
- ACI 9th Annual Paragraph IV Disputes Master Symposium
- Introduction to Biological Products, Including Vaccines, Biosimilars, Cell and Gene Therapies, and Other Advanced Therapies 2023
- IPPJ Committee Annual Pre-Meeting 2023
- ITCTLA Mock Hearing Program 2023
- LSPN North America Fall Conference 2023
- MCCA Creating Pathways to Diversity Conference and Diversity Gala 2023
- APABA-DC Awards & Installation Gala 2023
- GRx+Biosims Conference 2023
- CCWC 19th Annual Career Strategies Conference
- IAM Connect SEP Summit 2023
- Trade Secret IP Protection & Litigation Summit 2023
- IPWatchdog Third Annual Live Conference
- National Bar Association 98th Annual Convention and Exhibits
- ACI 10th Annual Women Leaders in Life Sciences Law Conference
- National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2023
- SABA North America Conference 2023
- ACI 14th Annual Summit on Biosimilars & Innovator Biologics
- Washington Lawyers’ Committee for Civil Rights and Urban Affairs – 2023 Wiley A. Branton Awards Luncheon
- Centerforce IP Strategy Summit 2023
- FDLI Annual Conference 2023
- LSPN North America Conference 2023
- Subtle Defiance: FDA’s Catalyst Response and Strategies for Challenging FDA Decisions
- VLA Champions of the Arts Awards and Gala 2023
- ACI 18th Annual Paragraph IV Conference
- ACI 40th Annual FDA Boot Camp
- Trade Secret IP Protection & Management West Coast Summit
- NBA CLS 36th Annual Corporate Counsel Conference
- LCCRSF 36th Annual Dr. Martin Luther King, Jr. Awards
- AIPLA IP Practice in Japan Committee Pre-Meeting and Dinner
- AIPLA Mid-Winter Institute 2023
- 23rd Annual Berkeley-Stanford Advanced Patent Law Institute
- Consero IP Forum for Life Sciences
- IAM Connect: Patent Policy and Litigation USA Conference 2022
- NAPABA Convention 2022
- Brooklyn Legal Services Champion of Justice Awards 2022
- 2022 EDTX Bench Bar Conference
- Connecticut Hispanic Bar Association's Annual Awards & Dinner 2022
- MCCA Creating Pathways to Diversity Conference and Diversity Gala
- CCWC 18th Annual Career Strategies Conference
- ACI 8th Annual Paragraph IV Disputes Master Symposium
- IAM and GCR: The SEP Summit
- ACI 39th Annual FDA Boot Camp
- 2022 AIPPI World Congress
- Northeast Black Law Students Association 2022 Job Fair
- National Bar Association 97th Annual Convention and Exhibits
- ACI 9th Annual Women Leaders in Life Sciences Law Conference
- The National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2022
- ACI 13th Annual Summit on Biosimilars & Innovator Biologics
- Axinn Sponsors Travelers Championship 2022
- Making One Call: Consolidating Costs for Complex Multi-Language Litigation
- Centerforce Women & Diversity in Law & IP 2022 Summit
- Concurrences IP & Antitrust: Hot Issues 2nd Edition Conference
- Washington Lawyers’ Committee for Civil Rights and Urban Affairs - 2022 Wiley A. Branton Awards Luncheon
- Volunteer Lawyers for the Arts - Champions of the Arts Awards 2022
- ACI 17th Annual Paragraph IV Conference
- Bay Area CHIZAI 43rd Seminar
- LCCRSF 2022 Dr. Martin Luther King, Jr. Annual Awards Event
- AIPLA DEI Program: Perspectives from LGBTQ Professionals
- GRx+Biosims Conference 2021
- FDLI 2021 Advertising and Promotion for Medical Products Conference
- ACI Hatch-Waxman and BPCIA Virtual Proficiency Series
- FDA Boot Camp
- IAM and GCR: The SEP Summit
- Centerforce IP 2022: New Beginnings
- ACI 8th Annual Women Leaders in Life Sciences Law Virtual Conference
- Pharmaceutical CEO Leadership: Collaboration in Pharma – Innovation
- Pharmaceutical CEO Leadership: Collaboration in Pharma – Working Together
- Making DEI Policies “Systemic” – Global and National Approaches
- ACI 12th Annual Summit on Biosimilars & Innovator Biologics
- The Alzheimer’s Association 2021 Hope on the Harbor Annual Gala
- Pharmaceutical CEO Leadership: Collaboration in Pharma
- AIPLA Diversity in IP Law: Where Are We Now? The Progression of Diversity, Equity and Inclusion in the Face of a Global Pandemic and Racial Reckoning
- FDLI Webinar: Biologic and Biosimilar Litigation and IP Rights
- ACI 15th Annual Paragraph IV Disputes Conference
- Volunteer Lawyers for the Arts - Champions of the Arts Awards
- 2021 Festival of Biologics: World Biosimilar Congress USA
- ACI 36th Annual FDA Boot Camp
- BALIF's 41st Annual Gala
- Bay Area CHIZAI Seminar: US Patent Litigation Strategies for Transfer
- Celesq® CLE Program: FDA in the Year of COVID – How FDA Tackled the Pandemic and What to Expect from FDA in 2021
- Intellectual Property: 2020 SCOTUS Decisions and Other Landmark Cases
- John Burke Pro Bono Virtual Breakfast
- ACI 7th Annual Women Leaders in Life Sciences Law Virtual Conference
- AABA's 44th Anniversary Virtual Gala
- If the BPCIA Should Fall – SCOTUS Decision Scenario Outlook
- The Potential Impact of the New Supreme Court Justice on FDA and FDA-Regulated Industry
- Centerforce IP Strategy Virtual Summit
- MCCA Creating Pathways to Diversity Virtual Conference
- AIPLA Diversity Roundtable
- U.S. Election Special
- The Alzheimer’s Association 2020 Hope on the Harbor Annual Gala
- ACI Paragraph IV Disputes Virtual Conference
- Corporate Counsel Women of Color (CCWC) and Hogan Lovells 16th Annual Career Strategies Conference
- ACI Summit on Biosimilars & Innovator Biologics Virtual Conference
- 2020 Connecticut Legal Conference
- Improving the JPO and Intellectual Property Practices: Views From the JPO
- ACI Paragraph IV on Virtual Trial COVID-19 Edition
- Joint Meeting: AIPLA and AIPPI Japan
- The Intersection of Artificial Intelligence and Intellectual Property: Hot Buttons in 2020
- Centerforce IP Strategy Virtual Summit: COVID-19 & Beyond
- BALIF's 40th Annual Gala
- Women’s Rights Law Reporter 50th Anniversary Symposium
- 2020 Festival of Biologics: World Biosimilar Congress USA
- Lawyers Committee for Civil Rights 2020 Dr. Martin Luther King, Jr. Awards Dinner
- IP Minds USA Summit
- BayHelix Chinese New Year Luncheon 2020
- "Should You ‘Google’ the Jury?”
- 2019 Centerforce IP Strategy Summit: Global & Domestic - Silicon Valley
- 2019 Centerforce 8th Annual IP Strategy Summit - NYC
- Navigating Patent Thickets in BPCIA Litigation
- AIPLA IP Practice in Japan Committee Pre-Meeting and Dinner
- CAPABA 2019 Annual Gala Dinner
- 2019 Festival of Biologics: World Biosimilar Congress Europe
- Managing Unconscious Bias to Increase Diversity and Promote Inclusion in Corporate and Law Firm Leadership
- NAPABA Northeast Regional / AABANY Fall Conference
- ACI 6th Annual Women Leaders in Life Sciences Law Conference
- GHLAF 3rd Annual Celebrating Leaders for Justice
- Medical Device and Life Sciences Patent Litigation in 2019: Subject Matter Eligibility Lessons from Recent Federal Court Decisions
- 2019 Medical Device Insights
- Division of Labor and Divided Infringement: Unified Strategies for Personalized Medicine and other Medical Treatment Inventions?
- Washington Lawyers’ Committee for Civil Rights and Urban Affairs - 2019 Wiley A. Branton Awards Luncheon
- ACI 10th Annual Summit on Biosimilars Conference
- 2019 Travelers Championship
- 9th Annual 10X Medical Device Conference
- 2019 WEX SPARK Health Conference
- ACI 13th Annual Paragraph IV Disputes Conference
- Recent IP Cases and Developments
- 2019 Centerforce Women, Diversity & Change Summit - Boston
- Volunteer Lawyers for the Arts - 50th Anniversary Gala
- AABA Bay Area 43rd Annual Gala
- 2019 Festival of Biologics: World Biosimilar Congress USA
- BALIF's 39th Annual Gala
- BayHelix Chinese New Year Luncheon 2019
- Barclays Credit Symposium
- 2018 Festival of Biologics: World Biosimilar Congress Europe
- The On-Sale Bar After Helsinn
- ACI 5th Annual Women Leaders in Life Sciences Law Conference
- ACI 9th Annual Summit on Biosimilars
- 35 U.S.C. 103 and the CAFC from District Courts
- ACI 12th Annual Paragraph IV Disputes Conference
- Relationship of Antitrust Law and Intellectual Property
- ACI 8th Annual Advanced Summit on Medical Device and MedTech Patents
- Hot Topics and Issues in the Biosimilars Space: Part Two
- Ethics and Intellectual Property Traps, Pitfalls and Adventures in IP Lawyering (2017)
- Connecticut Science Center Axinn Sponsorship
- ACI 4th Annual Women Leaders in Life Sciences Law Conference
- 2017 Centerforce Women in IP & Law Summit - Silicon Valley
- ACI 8th Annual Summit on Biosimilars
- 2017 Festival of Biologics: World Biosimilar Congress USA
- Magna’s Mock Crisis; Part III
- ACI 3rd Annual Post Grant PTO Proceedings Conference
- Operating Company vs Operating Company Litigation: A Proactive Defense
- Centerforce 2nd Annual Trademark & Copyright Summit
- ACI 7th Annual Advanced Summit on Medical Device and MedTech Patents
- IP Practice in Japan Pre-Meeting: IPR Estoppels in Litigation
- Intellectual Property Essentials for Entrepreneurs
- FDA's New Final Rule Implementing the MMA and Amending ANDA and 505(b)(2) Practice
- Centerforce 4th Annual IP Strategy Summit - Silicon Valley
- The Role of Factual Disputes in PTAB Institution Decisions in the Life Sciences
- Aligning Your Enforcement Strategy with Business Goals
- IP Practice in Japan Pre-Meeting: Defend Trade Secrets Act
- ACI 3rd Annual Women Leaders in Life Sciences Law Conference
- ACI 7th Annual Summit on Biosimilars
- Hot Topics and Issues in the Biosimilars Space: Part One
- ACI 6th Annual Summit on Biosimilars
- Patent Defense Strategies
- ACI 8th Annual Paragraph IV Disputes Conference
- 2013 ACI Biosimilars Conference
- ACI 7th Annual Paragraph IV Disputes Conference
- Trading in Secrets: Dealing with Employee and Data Mobility
- CBI 4th Life Sciences Congress on Paragraph IV Disputes
- Medical Device Litigation: A Trial Lawyer's Perspective
- ACI 6th Annual Paragraph IV Disputes Conference
- Willful Infringement Before and After Powell v. Home Depot
- The Bar Gets Higher: Royalty Damages After Uniloc
- ACI FDA Bootcamp 2012
- CBI 4th Annual Bio/Pharmaceutical Drug Safety Forum
- IQPC 6th Annual Summit on E-Discovery for Pharma, Biotech, and Medical Device Industries
- Non-Patent Marketing Exclusivities: Challenges, Opportunities and Current Controversies
- Patent Due Diligence - A Good Business Practice
- How Much Is That Patent Worth?
- How the Dynamics of Biosimilars Are Changing the Hatch-Waxman Landscape
- ACI 5th Annual Paragraph IV Disputes Conference
- AIPLA Mid-Winter Institute: Meeting of the Special Committee on the FDA: Discussion of the FDA Hearings on the Biologics Price Competition and Innovation Act
- ACI Hatch-Waxman Boot Camp
- Pitfalls in Royalty Calculations after Lucent and ResQNet
- Pre-Trial Tactics for Brands and Generics
- ACI Paragraph IV on Trial: Litigator's Master Class on Paragraph IV Pre-Trial Preparation
- CBI Pharmaceutical Congress on Paragraph IV Disputes and Settlements: Workshop Leader on Assessing Paragraph IV Litigation Strategies
- Assessing the Patent and FDA Strategies for Follow-On Biologics to Maximize Success
- Assessing the Patent and FDA Strategies for Follow-On Biologics to Maximize Success
- ACI Paragraph IV Disputes Advanced Master Class - Obtaining Optimal Terms and Mitigating Antitrust Concerns When Settling Paragraph IV Disputes
- CBI 3rd Annual Summit on Biosimilars
- Developing Profits from Patent Assets
- Intellectual Property and Ethics - Annual Review
- ACI Paragraph IV on Trial: Litigator's Master Class on Paragraph IV Pre-Trial Preparation
- CBI Pharmaceutical Congress on Paragraph IV Disputes
- LES International Annual Meeting
- Navigating the FDA's New 180-Day Generic Marketing Exclusivity Rulings
- University of Connecticut School of Law - Patent Law, Pharmaceutical Industry, and Antitrust
- Collaborating Attorney to the Connecticut Intellectual Property Notes
- Avoiding Compulsory Licenses in the Post-eBay Era
- View More ›